Scanning and combinatorial library services – Save 20% with code TRY-BXPLIB-20
November 24th, 2020

Back in 2013, I played a small role in response to what then seemed like the next potential pandemic — an outbreak of H7N9, an avian influenza virus. At the time, I was working with Novartis scientists, and we were…


November 18th, 2020

If you were there for the early days of synthetic biology, you probably remember it the way we do: a relatively small number of academic scientists toiling in labs to build key parts, like toggle switches, and tinkering with the…


November 11th, 2020

In the age of COVID-19, there has been a ton of scientific interest in nanobodies, or single-domain antibodies that can be used for finely targeted viral vaccines. It’s also been a hot topic among users of our BioXp™ system —…


November 4th, 2020

Without question, the global outbreak of the novel coronavirus 2019 (SARS-CoV-2) that causes COVID-19 has dominated scientific discussion and has been fodder for a wealth of publications as the world urgently races for a better understanding of the mechanism of…


October 28th, 2020

Breast cancer is now recognized as the most common malignancy worldwide among women, irrespective of age. Today’s standard of care and breast cancer management relies heavily on chemotherapy, hormone therapy, and targeted therapy. However, there is still much to be…


October 21st, 2020

The Codex DNA team really enjoyed attending this year’s virtual Global Synthetic Biology Conference hosted by SynBioBeta. If you missed the event, we’ve got you covered — here’s our take on highlights from the meeting. BioXp™ system in the spotlight…


October 14th, 2020

We’re continuing our blog series, looking at the DNA of Codex DNA — our incredible employees and their stories. Team member: Katie Lyons, Senior Scientist Came aboard: 2008 What do you do at Codex DNA? I develop and adapt biological…


October 6th, 2020

For cancer patients with few other treatment options, the need for new targeted immunotherapies is genuinely a matter of life or death. So how to accelerate the development of new therapies? One key component is automated DNA synthesis. That was…


September 30th, 2020

The treatment landscape for lymphoma – especially aggressive B-cell lymphomas — has been transformed by adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cells. Clinical trials with a focus on anti-CD19 CAR-T cell therapy have shown efficacy and long-term…


September 16th, 2020

For BioXp™ system users, antibody drug discovery is one of the most popular applications. That’s why we were delighted to participate in the recent Oxford Global Biologics virtual conference, with a presentation from our own Kirsty Maclean, Director of Applications…


September 10th, 2020

Several recent publications from the rockstar team at GigaGen illustrate how they are using the BioXp™ system to streamline antibody drug discovery workflows. It’s tough to overstate the importance of this area of research: monoclonal antibodies, antibody drug conjugates, and…


September 2nd, 2020

Today we’re excited to launch a blog series focused on our most valuable resource: our people. We wouldn’t be where we are today — enabling the tremendous science done by our customers — without the Codex DNA family. We’ll be…


August 26th, 2020

Please join us in welcoming the newest member of the Codex DNA family. Like its BioXp™ 3200 predecessor, the BioXp™ 3250 system is a fully automated, benchtop platform for synthetic biology workflows — but this one reduces the timelines for…


August 25th, 2020

SAN DIEGO – (GLOBE NEWSWIRE) – Codex DNA, Inc., creators of the world’s first fully automated system for high-throughput writing of DNA, today announced critical advancements in its development of the Digital-to-Biological Converter™ (DBC) platform. The platform will enable the direct…


August 19th, 2020

When it comes to improving life, there is no science more exciting than synthetic biology. The more we learn from reading the DNA or RNA code of every organism on this planet, the better equipped we are to make significant…


August 18th, 2020

SAN DIEGO – (GLOBE NEWSWIRE) – Today, Codex DNA, Inc., creators of the world’s first fully automated system for high-throughput DNA printing, announced the introduction of their next-generation platform, the BioXp™ 3250 system. This system reduces the timelines for identifying vaccine and…


July 16th, 2020

SAN DIEGO – (GLOBE NEWSWIRE) – Codex DNA, Inc., today announced the release of a new synthetic SARS-CoV-2 genome developed to accelerate research on the latest and the most dominant strain of the SARS-CoV-2 virus responsible for the COVID-19 pandemic. The…


April 9th, 2020

SAN DIEGO – (GLOBE NEWSWIRE) – Codex DNA, Inc., creators of the world’s first fully automated system for high-throughput writing of DNA, the BioXp™ 3200 system, today announced a newly developed and released suite of products and services designed to accelerate…


April 6th, 2020

SAN DIEGO – (GLOBE NEWSWIRE) – SGI-DNA, Inc., creators of the world’s first fully automated system for high-throughput writing of DNA, the BioXp™ 3200 system, today announced the business rebrand to Codex DNA, Inc. The rebrand signifies and solidifies the company’s…


February 18th, 2020

SAN DIEGO – (BUSINESS WIRE) – SGI-DNA, creators of the BioXp™ 3200 System and Gibson Assembly® Reagents, announces a focused effort to empower organizations to accelerate research focused on creating vaccines for SARS-CoV-2. SGI-DNA is building resources to support partners in the…


January 31st, 2020

SAN DIEGO – (BUSINESS WIRE) – SGI-DNA, creators of the BioXp™ 3200 System and Gibson Assembly® Reagents, has launched Vmax™ X2 Competent Cells, designed to generate two to four times more soluble protein in half of the time of current methods…


December 23rd, 2019

SAN DIEGO – (BUSINESS WIRE) – SGI-DNA, Inc., a company dedicated to developing transformative synthetic genomics technologies and revolutionary DNA data storage solutions, today announced the appointment of Brian Donnelly to the newly created position of Chief Commercial Officer. Mr. Donnelly…


November 19th, 2019

SAN DIEGO – (BUSINESS WIRE) – SGI-DNA announces the launch of Gibson Assembly® RapidAMP™ technology—a novel approach that allows for cell-free synthesis and amplification of transfection-ready quantities of synthetic DNA. The application has been integrated onto the BioXp™ 3200 Gene Builder and…


October 1st, 2019

SAN DIEGO – (BUSINESS WIRE) – Researchers from the University of Washington and Microsoft announced a DNA assembly strategy for nanopore data storage, reporting that the Gibson Assembly® Method was exceptionally effective in retrieving information stored in DNA. The strategy successfully…


September 9th, 2019

SAN DIEGO – (BUSINESS WIRE) – SGI-DNA, a company dedicated to developing transformative synthetic genomics technologies and revolutionary DNA data storage solutions, has completed a $25 million Series A financing round led by Northpond Ventures, with participation from Oxford Finance…


August 26th, 2019

SAN DIEGO – (BUSINESS WIRE) – SGI-DNA announces the launch of the Multi-Tile Assembly Cloning (MTAC) application for its BioXp™ 3200 Gene Builder, providing scientists with the ability to synthesize two genes and clone them with an optional constant fragment…


Questions? Suggestions? Need additional info?

The expertise of our scientists, engineers, and supporting teams is always available. Or call us: 858.228.4115